Clearing Minimal Residual Disease with Rituximab Consolidation Therapy

Seminars in Oncology

Volumn 31, Issue 1 SUPPL. 2, 2004, Pages 33-37

  Brugger, Wolfram ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Immu/Inf Dis ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; PREDNISOLONE; RECOMBINANT ALPHA INTERFERON; RITUXIMAB; VINCRISTINE;

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; HUMAN; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; MANTLE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; WHOLE BODY RADIATION;

EID: 1542513762     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.12.008     Document Type: Conference Paper

References (21)

1. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89: 3909-3918, 1997
2. Homing SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311:1471-1475, 1984
3. Hiddemann W, Brittinger G, Yiemann M, et al: Clinical characteristics and response to chemotherapy of mantle cell lymphoma-Results of a European survey. Blood 88:674a, 1996 (abstr)
4. Bierman PJ, Vose JM, Anderson JR, et al: High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15:445-450, 1997
5. Schouten HC, Kvaloy S, Sydes M, et al: The CUP trial: A randomized study analyzing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 11:S91-S94, 2000 (suppl 1)
6. Bensinger WI: Should we purge? Bone Marrow Transplant 21:113-115, 1998
7. Paulus U, Dreger P, Viehmann K, et al: Purging peripheral blood progenitor cell grafts from lymphoma cells: Quantitative comparison of immunomagnetic CD34+ selection systems. Stem Cells 15:297-304, 1997
8. Buckstein R, Imrie K, Spaner D, et al: Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 26:115-122, 1999 (suppl 14)
9. Goldberg SL, Pecora AL, Jennis AA, et al: Rituximab permits in-vivo purging and collection of tumor free stem cells prior to autologous transplantation for B-cell non Hodgkin's lymphoma. Blood 94:141a, 1999 (abstr)
10. Haioun C, Delfau-Larue MH, Beujean F, et al: Efficiency of in vivo purging with rituximab followed by high-dose therapy (HDT) with autologous peripheral blood stem cell transplantation (peripheral blood SCT) in B-cell non-Hodgkin's lymphomas (NHL). A single institution study. Blood 96:184a, 2000 (abstr)
11. Voso M, Pantel G, Weis M, et al: In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/ mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 109:729-735, 2000
12. Magni M, Di Nicola M, Devizzi L, et al: Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion. Blood 96:864-869, 2000
13. Bolwell BJ, Kalaycio M, Sobecks R, et al: Rituximab does not reduce CD34+ cell yield in patients mobilised with etoposide plus G-CSF. Blood 98:738a, 2001 (abstr)
14. Zelenetz AD, Chu G, Galili N, et al: Enhanced detection of the t(14;18) translocation in malignant lymphoma using pulsed-field gel electrophoresis. Blood 78:1552-1560, 1991
15. Gribben JG, Freedman A, Woo SD, et al: All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 78:3275-3280, 1991
16. Freedman AS, Neuberg D, Mauch P, et al: Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94:3325-3333, 1999
17. Bosch F, Jares P, Campo E, et al: PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: A highly specific marker of mantle cell lymphoma. Blood 84:2726-2732, 1994
18. Rambaldi A, Lazzari M, Manzoni C, et al: Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 99: 856-862, 2002
19. Buckstein RJ, Mangel J, Imrie K, et al: High dose therapy/ASCT consolidated with rituximab and or alpha interferon immunotherapy for relapsed follicular lymphoma prolongs progression free survival and achieves durable molecular remissions. Blood 100:647a, 2002 (abstr)
20. Mangel J, Leitch HA, Connors JM, et al: Intensive chemotherapy and autologous stem cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle cell lymphoma: A matched pair analysis. Blood 100:780a, 2002 (abstr)
21. Brugger W, Hirsch J, Repp R, et al: Treatment of follicular and mantle cell lymphoma with rituximab after high-dose chemotherapy and autologous blood stem cell transplantation: A multicenter phase II study. Blood 11:644a, 2002 (abstr 2532)